Vanda Pharmaceuticals’ (VNDA) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of Vanda Pharmaceuticals (NASDAQ:VNDA) in a research report report published on Monday,Benzinga reports. HC Wainwright currently has a $18.00 target price on the biopharmaceutical company’s stock.

Separately, StockNews.com began coverage on Vanda Pharmaceuticals in a research report on Thursday, December 19th. They issued a “hold” rating for the company.

Vanda Pharmaceuticals Stock Up 3.2 %

VNDA opened at $4.83 on Monday. Vanda Pharmaceuticals has a 52 week low of $3.46 and a 52 week high of $6.75. The business has a fifty day simple moving average of $4.86 and a 200-day simple moving average of $5.20. The firm has a market cap of $281.63 million, a P/E ratio of -17.25 and a beta of 0.76.

Insider Transactions at Vanda Pharmaceuticals

In other news, Director Stephen Ray Mitchell sold 5,000 shares of the business’s stock in a transaction dated Thursday, November 14th. The stock was sold at an average price of $5.17, for a total transaction of $25,850.00. Following the completion of the transaction, the director now directly owns 44,857 shares of the company’s stock, valued at approximately $231,910.69. The trade was a 10.03 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 8.90% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in VNDA. Meeder Asset Management Inc. acquired a new position in shares of Vanda Pharmaceuticals during the second quarter worth $39,000. ORG Wealth Partners LLC acquired a new position in shares of Vanda Pharmaceuticals during the 3rd quarter worth about $40,000. SG Americas Securities LLC purchased a new position in shares of Vanda Pharmaceuticals in the 2nd quarter valued at about $61,000. China Universal Asset Management Co. Ltd. increased its holdings in shares of Vanda Pharmaceuticals by 64.0% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 11,211 shares of the biopharmaceutical company’s stock valued at $53,000 after acquiring an additional 4,374 shares during the last quarter. Finally, XTX Topco Ltd acquired a new stake in shares of Vanda Pharmaceuticals during the 2nd quarter worth about $75,000. Institutional investors and hedge funds own 88.14% of the company’s stock.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.